London, August 24, 2020 – Collaborative Community Against Coronavirus C.I.C., a not-for-profit collaborative dedicated to ensuring that the worldwide community is better prepared for the epidemics caused by viruses, today announced that using its existing networks, the team has identified groups of compounds suitable for testing against live SARS-CoV-2 virus, carried out on contract at a screening facility in Belgium.
We were delighted when our first screening returned hit compounds with antiviral efficacy equivalent to the marketed drug, remdesivir, in the screening assay. Follow-up compounds, rapidly synthesized at a UK-based contract research company, showed improved antiviral activity and confirmed that we have identified our first anti-coronavirus series. Work to improve these compounds is on-going.
For media, investor & collaborator enquiries, please contact: Collaborative Community Against Coronavirus C.I.C.
Dr Eddy Littler & Dr Richard Angell